Description
CJC-1295 / Ipamorelin Blend is a dual-peptide formulation designed for research involving growth hormone-related signaling pathways and receptor-mediated communication systems.
CJC-1295 is a synthetic peptide studied for its interaction with growth hormone-releasing hormone (GHRH) receptors, while Ipamorelin is a selective agonist of the ghrelin (GHS-R1a) receptor. Each compound is widely examined individually for its role in peptide-mediated signaling, and when combined, they provide a complementary framework for investigating coordinated receptor activation and pathway interaction.
In laboratory settings, this blend is utilized to explore how GHRH receptor signaling and ghrelin receptor activation interact within controlled experimental models. The combination allows for investigation of signaling cascade integration, receptor-specific activity, and peptide-driven communication across growth hormone-related pathways.
CJC-1295 / Ipamorelin Blend has been explored in research involving:
- Growth hormone-related signaling pathways and receptor interaction
- GHRH receptor and ghrelin receptor (GHS-R1a) activation dynamics
- Peptide-mediated signaling cascade integration
- Multi-receptor pathway coordination and communication
- Controlled experimental models involving dual-peptide systems
By combining two complementary peptides into a single formulation, this blend enables streamlined investigation of coordinated signaling activity and receptor interaction within growth hormone-related systems.
Each vial contains a lyophilized peptide blend consisting of CJC-1295 and Ipamorelin.
Research Use Only (RUO). Not for human or veterinary use.
Reviews
There are no reviews yet.